Cardiff Oncology Corp (CRDF): Rasio rega marang pendapatan

Cardiff Oncology, Inc. (CRDF) focuses on developing targeted therapies based on a rigorous scientific approach and clinician expertise. The historical P/S trend on this GURU.Markets chart, where 101.30 captures the current indicator value, highlights the pressure from pharma behemoths in the battle for patents. High R&D expenditures define the financial profile, keeping margins at a preparatory level.

CRDF Multiplikator P/S Cardiff Oncology (04.07.2022 - 15.11.2026)

Cardiff Oncology Inc. (CRDF) - rincian metrik lan laporan keuangan

- kuotasi saiki lan rata-rata prakiraan nilai:

Rega bursa Cardiff Oncology Inc.|CRDF - Bagan rega target

- data kapitalisasi bursa:

Nilai pasar Cardiff Oncology|CRDF - Nilai Total Perusahaan

- statistik nilai buku emiten:

Nilai Aset Bersih saben Saham Cardiff Oncology|CRDF - Kapitalisasi Buku|Rasio Nilai Pasar marang Ekuitas cardiffoncology.com|CRDF - Gunggung Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

Utang marang Modal Cardiff Oncology, Inc.|CRDF - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Cardiff Oncology Corp|CRDF - Gunggung utang perusahaan|Utang marang modal buku Cardiff Oncology, Inc.|CRDF - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Cardiff Oncology|Likuiditas darurat cardiffoncology.com

- data bathi lan kelipatan valuasi:

CRDF - Bathi resik perusahaan|Penghasilan resik sing dikarepake Cardiff Oncology, Inc.|CRDF - Pangali P/E|Pangali Forward P/E Cardiff Oncology Inc.|CRDF - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi operasional sadurunge panyusutan Cardiff Oncology, Inc.|CRDF - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Cardiff Oncology|CRDF - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan cardiffoncology.com|CRDF - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Cardiff Oncology, Inc.

- rincian pendapatan lan dodolan emiten:

CRDF - Pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan Cardiff Oncology|CRDF - Multiplikator P/S|Kapitalisasi marang prakiraan pendapatan Cardiff Oncology, Inc.

Ringkesan analitik perusahaan:Cardiff Oncology Corp

The P/S ratio determines the market value of a single ruble of revenue, allowing investors to distinguish between objective capitalization and speculative market expectations. By analyzing the price-to-sales multiple, one can assess the valuation volatility of Cardiff Oncology, Inc. (CRDF), where a high price-to-sales ratio reflects confidence in the success of innovative PLK1 inhibitors amid fierce biotech competition and dependence on clinical trial results.

Perusahaan pesaing

INCY - Rega marang dodolan|Rasio rega marang pendapatan hutch-med.com HCM|Nuvation Corp - Rasio rega marang pendapatan|DAWN - Rasio rega marang pendapatan|Rega marang dodolan Monopar Therapeutics|INBX: Multiplikator P/S|Multiplikator rega marang pendapatan I-Mab IMAB|Kapitalisasi marang pendapatan FENC|Rega marang dodolan Heron Therapeutics, Inc. HRTX|Kapitalisasi marang pendapatan NVCT (Nuvectis Pharma, Inc.)|CHRS (Coherus BioSciences) - Rasio kapitalisasi pasar marang pendapatan|Corbus Pharmaceuticals - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan BYSI (BeyondSpring)|BioAtla - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan LIXT (Lixte Biotechnology Holdings)|CTXR: Multiplikator P/S|Rega marang dodolan cellectar.com (CLRB)|Rasio rega marang pendapatan BioLineRx|CANF: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S APRE|Multiplikator P/S Kazia Therapeutics Ltd (KZIA)|Rasio rega marang pendapatan Silexion Therapeutics Corp. SLXN|NCNA (nucana.com) - Rasio rega marang dodolan|CMRX: Kapitalisasi marang pendapatan|Rega marang dodolan Cyclacel|GTHX: Multiplikator P/S|Kronos Bio Corporation (KRON) - Multiplikator P/S|KTRA (kintara.com) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ONCT (Oncternal Therapeutics)|Rasio rega marang pendapatan Portage Biotech (PRTG)